Natera Just Proved the Growth Story. The Math Says There's Still a Disconnect — But Not Where You Think.

Natera's stock jumped 20% today after Q2 earnings, hitting a fresh 52-week high and the biggest single-day gain since November 2024. The company reported $752.8 million in revenue — a 13.8% beat over Wall Street estimates and 37.7% growth year over year — then raised full-year guidance by $100 million to $2.85 billion–$2.91 billion. Oncology test volumes surged 57.2%. Signatera earned FDA companion diagnostic approval for bladder cancer, plus clearances in Japan and the EU.

The market reacted like the thesis had been proven for the first time. It had. The disconnect now is whether the math still supports the multiple.

Oncology volume is the real variable, and it's accelerating. Natera processed 1.04 million tests in Q2, the second straight quarter above one million. But the headline isn't volume — it's oncology volume. MRD (molecular residual disease, the measurement of leftover cancer DNA after treatment) oncology units grew 34,000 sequentially, the largest quarter-over-quarter jump to date. Oncology test volume reached 296,700 in Q2, up 57.2% from 188,800 a year ago. This is the growth engine the prenatal testing and transplant monitoring base was supposed to become. It is.

Revenue growth is outpacing volume growth, and that matters. Annualized revenue growth averaged 37.7% in Q2 while volume grew 22.4%. The gap means price increases and mix shift toward higher-value oncology tests are adding leverage on top of unit growth. Gross margin hit 64.5%, up from 63.4% a year ago, and the operating loss narrowed to $75.8 million from $110.4 million. That's operating leverage showing up on a revenue base that more than doubled in two years.

The guidance raise tells you management sees more. The $100 million midpoint increase pushes the full-year outlook to $2.85B–$2.91B, backed by an expected 31% growth rate excluding revenue true-ups (one-time adjustments to prior-period billings). That's a deliberate acceleration, not a gentle adjustment. Management also expects positive cash flow for 2026, and the company ended the quarter with $1.09 billion in cash against only $80.3 million in debt.

AInvest's aggregate signal labels the stock a Buy, and the composite analysis rating of 4.07 out of 5 reflects broad sell-side confidence. JPMorgan raised its price target to $360 from $315 after the report. BTIG pushed its target to $320 from $290.

The problem is what the stock costs to play the next leg. Natera's market cap sits at approximately $45.7 billion. On trailing sales, that's about 16.6 times. Forward sales at the midpoint of new guidance would be roughly 16.0 times. The company is still losing money on a GAAP basis — EPS came in at -$0.47 for the quarter. Free cash flow for the trailing twelve months was $51.2 million, down 51% year over year. That growth story is real, but the price already assumes execution stays flawless.

And then there's the insider data. Over the past six months, insiders executed 251 trades — all sales, zero purchases. The executive chairman sold 311,157 shares worth roughly $62.3 million. The CEO sold 66,283 shares worth $14.7 million. You can argue these are scheduled sales or diversified portfolios, and maybe that's the case. But at 20% above where the stock was a month ago, with no insider buying at any price point, the signal is noisy at best.

What the market hasn't priced in — or is mispricing. FIND-CRC (a colorectal cancer screening trial) enrollment is expected to wrap in Q3, and Signatera's bladder cancer FDA approval opens a new label in a large, underserved market. Japan and EU clearances expand the international runway. These are real milestones that could drive another step-function in oncology volumes. But they're also the kind of pipeline progress that moves into the stock gradually — not the kind that justifies a sudden re-rating after a 40% year-to-date gain.

The break condition is simple. If Natera continues clearing oncology milestones and the revenue trajectory holds at the 30%+ pace management has laid out, the multiple has room to normalize as the company approaches profitability. But if oncology volume growth decelerates or the path to positive free cash flow stretches beyond 2026, the current premium becomes hard to defend.

At 16 times forward sales on a business still burning cash, the growth story is proven — but the entry point isn't attractive for new positions. The insiders know the playbook. They're just the ones cashing out of it.